OpGen

OpGen is a precision medicine company headquartered in Rockville, Maryland. The company employs 48 people and generates annual revenue of $2 million. OpGen operates on the NASDAQ stock exchange under the symbol OPGN. OpGen develops diagnostic solutions that optimize the treatment of life-threatening, drug-resistant infections. They focus on creating highly multiplexed syndromic molecular panels to address antimicrobial resistance, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms. These solutions are intended to guide antibiotic therapy selection and ultimately improve patient care. The company's approach leverages the power of molecular microbiology and innovative diagnostic technologies. OpGen's goal is to transform patient care by providing clinicians with precise information to guide treatment decisions and combat the global threat of antimicrobial resistance. For more information about OpGen and their products and services, visit their website at opgen.com.